Medicare will only cover a new Alzheimer’s drug that costs $28,000 a year for patients who are enrolled in clinical trials, President Joe Biden’s administration announced preliminarily Tuesday. Aduhelm, made by Biogen, was approved by drug regulators last year. Since then, the Centers for Medicare & Medicaid Services (CMS) has been assessing whether to cover the drug. In a preliminary decision memorandum, CMS said it would cover Aduhelm only for patients in “CMS approved randomized controlled trials” or trials sponsored by the National Institutes of Health. The trials must satisfy certain criteria, including being conducted in hospital-based outpatient settings. A Biogen spokesperson told The Epoch Times in an email that the proposed coverage “denies the daily burden of people living with Alzheimer’s disease” and would “exclude almost all patients who may benefit.” “We will continue to urge CMS to align Medicare coverage for the class of amyloid-directed therapies with the populations studied in the …